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1  | INTRODUC TION
Hepatitis E virus (HEV) is mainly spread in humans by contaminated 
food and water, but it is increasingly being recognized as a threat to 
blood transfusion safety because of its documented transmission by 
means of viremic blood components.1,2
The risk of transfusion-related infection is generally estimated 
on the basis of the prevalence of HEV RNA among blood donors. 
Nucleic acid testing (NAT) has detected a high rate of viremic do-
nations (up to one in 600) in a number of European countries.1,2 
There is some evidence of high prevalence of viremia and anti-HEV 
reactivity among donors in Abruzzo (Central Italy),3 although a ret-
rospective analysis conducted in plasma pools by the Italian National 
Blood Centre suggests that the pattern of HEV circulation might be 
different in other Italian regions.4
However, pooling procedures can limit the analytical sensi-
tivity of NAT and so donations should undergo individual test-
ing. Furthermore, a number of reports indicate that the infection 
pressure is not stable over time. This implies that NAT yields de-
termined in the relatively short time frame of a prevalence study 
may not be entirely representative of the risk of transfusion-related 
transmission, and serological incidence data may be more useful.
Taking advantage of a longitudinal biorepository financed by the 
European Union,5 we calculated the prevalence and incidence of 
HEV infection over the last ten years in donors from Northern Italy 
and used these data to estimate the risk of the transfusion-related 
transmission of HEV infection.
2  | SUBJEC TS AND METHODS
The study was conducted within the framework of the EU-funded 
Blood and Organ Transmissible Infectious Agents (BOTIA) project 
(SP23-CT-2006-006487).5 The study protocol was approved by our 
local Institutional Review Board and conducted in accordance with 
Italian Authorisation No. 9/2014 of 11 December 2014 concerning 
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personal data protection for scientific research purposes. The do-
nors underwent biochemical and virological testing as prescribed by 
Italian regulations.
Frozen plasma samples from donations collected at the 
Department of Transfusion Medicine and Hematology in Lecco in 
2015-2016 were tested for the presence of circulating HEV RNA by 
means of individual NAT (ID-NAT), using the Procleix HEV assay and 
Panther instruments (Grifols, Barcelona, Spain), with a 95% limit of 
detection of 7.9 IU/mL. Donors found to be initially ID-NAT reactive 
were re-tested on a different aliquot, tested for anti-HEV IgG and 
IgM (DiaPro HEV IgG and HEV IgM kits; Diagnostic BioprobesSrl) 
and followed up at subsequent donations.
A subset of samples was also analysed for the presence of an-
ti-HEV IgG in order to study the prevalence of past exposure to HEV. 
Confirmation of initially reactive samples was based on repeated 
testing and, when possible, on follow-up.
Finally, in order to evaluate the dynamics of HEV infection over 
time, we identified a subgroup of donors who had given two serial 
samples over a relatively long follow-up: that is the first at the start 
of the BOTIA project in 2007-2010, and the second in 2017. These 
samples were tested for anti-HEV IgG, and the incidence of infec-
tion was calculated as the number of seroconversions by the total 
number of initially negative cases, multiplied by the median number 
of years of follow-up and expressed as a number per 10 000 per 
year. The risk of receiving an infectious blood unit was estimated 
using two methods: HEV RNA yield and serological incidence, as-
suming a viremia duration of four weeks in the case of asymptomatic 
infections.6
3  | RESULTS
Figure 1 summarizes the study results.
A total of 9726 donor samples were collected for the HEV RNA 
study: 7253 (74.5%) taken from males and 2473 (25.5%) taken from 
females, with a mean age of 43 years (range: 18-67).
The ID-NAT assay showed that ten of the samples were initially 
reactive, but repeated testing confirmed reactivity in only one. 
The donor was a 63-year-old female who had normal alanine ami-
nostransferase levels (ie 22U/L) and was fully asymptomatic at the 
pre-donation examination. She subsequently seroconverted to being 
anti-HEV IgG positive. None of the nine donors whose initial reac-
tivity was not confirmed seroconverted during the follow-up period. 
Thus, the prevalence of HEV RNA was 0.01% (95% CI 0.00%-0.06%).
In addition, 767 samples (76.7% males, 23.3% females, mean 
age 43 years) were analysed in order to determine the prevalence 
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of anti-HEV. Anti-HEV IgG reactivity was confirmed in fifty-two do-
nors (45 males and 7 females), thus indicating an overall prevalence 
of IgG of 6.8% (95% CI 5.1%-8.8%). None of them was concomitantly 
anti-HEV IgM or HEV RNA positive. The prevalence of anti-HEV IgG 
increased across age strata, ranging from 1% (95% CI 0.0%-5.7%) 
in donors of 18-30 years to 11.1% (95% CI,7%-16.5%) in those of 
50 years or older.
Finally, a subset of 320 donors contributed 640 paired samples 
collected between 2007 and 2017 (mean interval between sampling: 
9 years, range 8-10). Thirty-one donors (9.7%; 95% CI: 6.7-13.5%) 
were anti-HEV IgG positive at baseline, and all of them were still 
reactive when the second sample was collected. Two of the 289 do-
nors who were initially anti-HEV-IgG negative had seroconverted 
by the time of the follow-up sample: they were both males and, in 
2017, were, respectively, 48 and 49 years old. The incidence was 7.6 
(95% CI 2.1-27.5) per 10 000 per year. The estimated risk of transfu-
sion-related infection based on HEV RNA yields was 1/10000 blood 
donations (the upper limit of the 95% CI was 1/1,666); the estimate 
based on the incidence data was 1/16666 blood donations (95% CI 
1/4350-1/57000).
4  | DISCUSSION
Our study combined HEV viremia and serological data in order to 
estimate transfusion risk over a ten year period. Using high sensi-
tive individual testing, we found that only one of the ten initially 
HEV RNA reactive samples in our series was found to be truly 
viremic, accounting for one out of almost ten thousand blood do-
nations. In addition, the overall seroprevalence of anti-HEV IgG 
was 6.8%. These data indicate that the frequency of current and 
past HEV infections among blood donors in northern Italy is one 
of the lowest so far reported in Europe. According to recent re-
views, the prevalence of HEV RNA positivity ranges from 1/762 in 
the Netherlands to 1/8416 in Austria and that of anti-HEV ranges 
from 12% in England to 53% in south-western France.2 Our find-
ings are also very different from those observed in Abruzzo, a 
region in central Italy. According to Lucarelli et al 3, almost half 
of the subjects donating blood in L’Aquila during the first months 
of 2014 showed serological signs of previous HEV exposure, and 
one out of 166 had detectable viremia. The highly endemic nature 
of the infection in this area has been attributed to local dietary 
habits favouring zoonotic transmissions, but another possibility is 
contaminated water, as the circulation of some faecal pathogens 
increased in the area of L’Aquila for several years after the cata-
strophic earthquake in 2006.7
Given that nine of the ten initially NAT-reactive samples were 
not confirmed by further testing or at serological follow-up, it seems 
that a single determination of HEV RNA has little positive predictive 
value. The impact of false-positive results might be more evident 
when testing samples at low risk of infection, like blood donors. It 
is therefore possible that some of the variability in the prevalence 
rates recorded in previous studies is related to methodological 
differences.
As expected, the prevalence of anti-HEV increased with age, 
thus reflecting a cohort effect and the long-term persistence of anti-
body reactivity after primary infection. The fact that the age-related 
increases in prevalence were relatively uniform (data not shown) 
suggests that no major outbreak has occurred since the 1950s. Our 
prospective repository of biological samples allowed us to calcu-
late the incidence of HEV infection over a ten year period, which 
proved to be 7.6/10 000 per year and is substantially lower than the 
calculated incidence in other European countries such as Germany 
(35/10 000 per year).8 Furthermore, these data allowed us to esti-
mate the local transfusion-related risk of infection using a method 
based on the assumption that the viremic phase (and therefore, the 
infectiousness of the blood products collected during active infec-
tion) lasted four weeks in each seroconverting blood donor.6 On the 
basis of this calculation, approximately one out of 16 000 donors 
should be positive at any given time, a figure that is in line with the 
prevalence of HEV RNA found in this study and confirms that in-
fection pressure remained quite stable in northern Italy during the 
considered ten years.
The limitations of this study include the fact that we could not 
look back on HEV transmission because all of the samples were 
coded and blinded to investigators, according to current regula-
tions. Secondly, the findings cannot be extended to the Italian 
population as a whole because of the geographical heterogene-
ity of the circulation of HEV. However, our study population was 
representative of the local community of blood donors as it in-
cluded donors living in urban, suburban, rural and mountain areas. 
Lombardy is the most highly populated region in Italy, and its 
transfusion system provides 24% of the total Italian blood sup-
ply. Although the circulation of HEV is minimal in comparison with 
other European countries, our data indicate that some tens to 
hundreds of HEV-infected blood components a year may be trans-
fused into blood recipients. Some of them, such as immunocom-
promised patients, are susceptible to the development of acute or 
chronic liver failure, or a chronic infection that may rapidly prog-
ress to liver cirrhosis and death.1,2
The findings of this study may be useful for the regional and na-
tional blood authorities responsible for making policy decisions given 
that recent European guidelines1 recommend that HEV screening 
policies should be based on local risk assessment studies. Whether 
or not to introduce HEV NAT screening therefore requires careful 
consideration: donor screening may very effectively minimize iatro-
genic HEV infection, but it is very costly and can be expected to have 
a relatively minor impact on the number of HEV infections in the 
population as a whole because the vast majority of new infections 
seems to be due to dietary exposure.1,2
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